Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Phase4 Partners, formerly known as Nomura Phase4 Ventures, is a London-based venture capital firm that focuses on investing in companies transforming healthcare. The firm was established to support innovative ventures in biotechnology, medical devices, digital health, and diagnostics. Phase4 Partners operates from its office located at 4th Floor, Cavendish Place, London W1G 0QF, England, United Kingdom.
The firm has a strong reputation in the European life sciences sector, having spun out from Nomura in 2015. At the time of the spinout, a portion of its assets under management was sold to funds managed by HarbourVest Partners. Phase4 Partners has made over 30 investments since its inception, primarily in mid-to-late stage life science companies, collaborating with top-tier US and European venture capital firms.
Currently, the team consists of eight professionals, including Managing Partner Denise Pollard-Knight, who has a notable background in healthcare venture capital. The firm emphasizes its commitment to enhancing patient care and improving health outcomes through strategic investments.
Phase4 Partners specializes in mid-to-late stage investments within the life sciences sector, particularly focusing on biotechnology, medical devices, digital health technologies, and diagnostics. The firm seeks to partner with companies that are at the forefront of healthcare innovation, emphasizing therapies, next-generation devices, and AI-driven diagnostics. Typical investment checks range from $15 million to $30 million per company, with portfolio company valuations at entry typically between $50 million and $100 million.
Geographically, Phase4 Partners is focused on the UK market but actively collaborates with leading venture capital firms in the US and Europe. The firm operates on a co-investment model, which allows it to maximize the impact of its investments while driving significant advancements in healthcare. Phase4 Partners looks for companies that demonstrate strong potential for growth and innovation in their respective fields.
Phase4 Partners has a diverse portfolio of notable companies in the life sciences sector. Key portfolio companies include:
These companies represent Phase4 Partners' commitment to investing in transformative healthcare solutions that enhance patient care and improve health outcomes.
Denise Pollard-Knight - Managing Partner. Denise has a distinguished career in healthcare venture capital, having previously worked at Nomura Phase4 Ventures. She was recognized with the Women in the City Award in 2008 for her contributions to the field. Denise's expertise spans various aspects of life sciences investing, making her a key asset to Phase4 Partners.
To pitch to Phase4 Partners, founders should send an email to denise@p4p.tech. It is recommended to include a comprehensive pitch deck that outlines the business model, market opportunity, and team background. The firm values clarity and detail in presentations, so including relevant data and projections is crucial.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, especially from trusted sources within the healthcare or venture capital sectors, to facilitate initial discussions.
In recent activity, Phase4 Partners has continued to focus on mid-to-late stage investments in the life sciences sector. The firm has made over 30 investments since its inception, collaborating with top-tier US and European VCs. Notably, the firm participated in significant funding rounds for companies like Mereo BioPharma, which raised $119 million for its mid-stage clinical portfolio acquisition.
Phase4 Partners has maintained a strong presence in the healthcare investment community, leveraging its expertise to support transformative solutions in biotechnology and digital health. The firm remains committed to enhancing patient care and improving health outcomes through its strategic investments.
What are Phase4 Partners' investment criteria?
Phase4 Partners invests in mid-to-late stage companies within the life sciences sector, focusing on biotechnology, medical devices, digital health, and diagnostics. The firm typically invests between $15 million and $30 million per company, targeting firms with valuations between $50 million and $100 million at entry.
How can I apply or pitch to Phase4 Partners?
Founders interested in pitching to Phase4 Partners should reach out via email at denise@p4p.tech. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes Phase4 Partners different from other venture capital firms?
Phase4 Partners distinguishes itself through its deep expertise in life sciences and its co-investment model with top-tier US and European VCs. This approach allows the firm to leverage strategic partnerships and enhance the impact of its investments.
What is the geographic scope of Phase4 Partners' investments?
The firm primarily focuses on the UK market but actively collaborates with leading venture capital firms in the US and Europe, expanding its reach and influence in the life sciences sector.
What type of post-investment involvement does Phase4 Partners have?
Phase4 Partners adds value to its portfolio companies through strategic guidance, leveraging its extensive network in the healthcare sector, and facilitating partnerships with other leading venture capital firms. The team provides critical insights and support throughout the investment lifecycle.
What is the typical fund size or assets under management for Phase4 Partners?
While specific figures for the current fund size or assets under management are not disclosed, Phase4 Partners has made over 30 investments since its inception, indicating a significant level of activity in the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.